Vaccine Development for SARS-CoV-2 and Zoonotic Diseases

Dear Colleagues,

One of the best ways to stop the spread of infectious illnesses, such as the devastating coronavirus disease 2019 (COVID-19), is through vaccination. Because more is known today about the human immune system, the development of vaccines has been expedited, and the creation of vaccines has significantly increased life expectancy and human health worldwide. Countless lives have been saved through vaccination, which has also reduced medical costs and raised the standard of living. Traditional vaccination designs still require development in order to better comprehend their impact on human immune systems. Several immune-related issues regarding newly developing human pathogenic viruses must be taken into account. In addition to the development of mRNA-based vaccines, proteomics or subunit vaccine also serve as important domains in the development of vaccines. Modern reverse vaccinology techniques enable the development of a targeted adaptive immune response. Numerous vaccines against human infections have been created using the epitope prediction technique. This involves the creation of a possible vaccine candidate against "Plasmodium vivax" based on the epitope (AMA-1). A potential vaccination against “Acinetobacter baumannii” was recently tested in mice in 2019 using a computationally predicted multi-epitope immune response. Similar to this, the effectiveness of computationally predicted B cell epitopes in diagnostics against “Trypsonoma vivax” was also validated. Such methods have been used, for example, to combat the Ebola virus, Marburg virus, Crimean–Congo hemorrhagic fever virus, and Mokola Rabies virus, which are all human pathogenic viruses. This also highlights the possible effects of techniques based on reverse vaccinology for developing vaccines against human infections. These vaccines are developed using the proteomes of different pathogens. Hence, this demonstrates the capability of proteome-based vaccines and their role in containing diseases. Therefore, the current issue will focus on the development of different vaccines for different diseases using proteins.

With these advancements, we welcome the submission of manuscripts on the following aspects:

• Protein-based vaccine design;
• Epitope platform development;
• Improving proteome-based vaccine prediction;
• Proteomics-based mRNA vaccine design;
• Identification and characterization of vaccine targets in the proteomes;
• Development and improvement of current peptide-based vaccines.

Dr. Abbas Khan
Prof. Dr. Dongqing Wei
Dr. Syed Shujait Ali
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• vaccine development
• SARS-CoV-2
• zoonotic diseases
• proteomic